Health care stocks rose Tuesday afternoon with the NYSE Health Care Index gaining 0.3% and the Health Care Select Sector SPDR Fund (XLV) adding 0.5%.

The iShares Biotechnology ETF (IBB) climbed 1.3%.

In corporate news, Recursion Pharmaceuticals (RXRX) shares jumped 11% after the company gained full rights to REV102, a drug candidate for hypophosphatasia, after acquiring Rallybio's (RLYB) interest in the program. Rallybio surged 43%.

Pfizer (PFE) Chief Corporate Officer Sally Susman will leave the company at the end of the year. Pfizer shares rose 1.1%.

ProKidney (PROK) shares soared more than sixfold after the company said its investigational therapy rilparencel stabilized kidney function in a group of patients with chronic kidney disease and diabetes who received two injections about three months apart in a phase 2 trial, replicating the dosing regimen of its ongoing phase 3 study.

Maze Therapeutics' (MAZE) development strategy using genetic validation is seen as promising in terms of its target identification strategy and application to the nephrology and metabolic disease segments, Wedbush Securities said. Wedbush started coverage of the company with an outperform rating and $17 price target. Maze shares jumped 24%.